Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement

The outbreak of the SARS‐CoV‐2‐induced coronavirus disease 2019 (COVID‐19) pandemic re‐shaped doctor‐patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant num...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Allergy
Κύριοι συγγραφείς: Vultaggio, Alessandra, Agache, Ioana, Akdis, Cezmi A., Akdis, Mubeccel, Bavbek, Sevim, Bossios, Apostolos, Bousquet, Jean, Boyman, Onur, Chaker, Adam M., Chan, Susan, Chatzipetrou, Alexia, Feleszko, Wojciech, Firinu, Davide, Jutel, Marek, Kauppi, Paula, Klimek, Ludger, Kolios, Antonios, Kothari, Akash, Kowalski, Marek L., Matucci, Andrea, Palomares, Oscar, Pfaar, Oliver, Rogala, Barbara, Untersmayr, Eva, Eiwegger, Thomas
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley and Sons Inc. 2020
Θέματα:
Eaaci Position Papers
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7300800/
https://ncbi.nlm.nih.gov/pubmed/32500526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.14407
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια